Literature DB >> 16921399

Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents.

G Nowak1, A Partyka, A Pałucha, B Szewczyk, J M Wierońska, M Dybała, M Metz, T Librowski, W Froestl, M Papp, A Pilc.   

Abstract

BACKGROUND AND
PURPOSE: A crucial role for the GABAB receptor in depression was proposed several years ago, but there are limited data to support this proposition. Therefore we decided to investigate the antidepressant-like activity of the selective GABAB receptor antagonists CGP 36742 and CGP 51176, and a selective agonist CGP 44532 in models of depression in rats and mice. EXPERIMENTAL APPROACH: Effects of CGP 36742 and CGP 51176 as well as the agonist CGP 44532 were assessed in the forced swim test in mice. Both antagonists were also investigated in an olfactory bulbectomy (OB) model of depression in rats, while CGP 51176 was also investigated in the chronic mild stress (CMS) rat model of depression. The density of GABAB receptors in the mouse hippocampus after chronic administration of CGP 51176 was also investigated. KEY
RESULTS: The GABAB receptor antagonists CGP 36742 and CGP 51176 exhibited antidepressant-like activity in the forced swim test in mice. The GABAB receptor agonist CGP 44532 was not effective in this test, however, it counteracted the antidepressant-like effects of CGP 51176. The antagonists CGP 36742 and CGP 51176 were effective in an OB model of depression in rats. CGP 51176 was also effective in the CMS rat model of depression. Administration of CGP 51176 increased the density of GABAB receptors in the mouse hippocampus. CONCLUSIONS AND IMPLICATIONS: These data suggest that selective GABAB receptor antagonists may be useful in treatment of depression, and support an important role for GABA-ergic transmission in this disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16921399      PMCID: PMC2014666          DOI: 10.1038/sj.bjp.0706845

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

1.  GABA(B) receptor inhibition causes locomotor stimulation in mice.

Authors:  G Colombo; S Melis; G Brunetti; S Serra; G Vacca; M A Carai; G L Gessa
Journal:  Eur J Pharmacol       Date:  2001-12-14       Impact factor: 4.432

2.  Localization of the GABAB receptor 1a/b subunit relative to glutamatergic synapses in the dorsal cochlear nucleus of the rat.

Authors:  Rafael Luján; Ryuichi Shigemoto; Akos Kulik; José M Juiz
Journal:  J Comp Neurol       Date:  2004-07-12       Impact factor: 3.215

Review 3.  The 'ABC' of GABA receptors: a brief review.

Authors:  M Chebib; G A Johnston
Journal:  Clin Exp Pharmacol Physiol       Date:  1999-11       Impact factor: 2.557

4.  Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits.

Authors:  Cedric Mombereau; Klemens Kaupmann; Martin Gassmann; Bernhard Bettler; Herman van der Putten; John F Cryan
Journal:  Neuroreport       Date:  2005-02-28       Impact factor: 1.837

5.  G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons.

Authors:  C Lüscher; L Y Jan; M Stoffel; R C Malenka; R A Nicoll
Journal:  Neuron       Date:  1997-09       Impact factor: 17.173

6.  Involvement of GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats.

Authors:  Y Nakagawa; T Ishima; Y Ishibashi; T Yoshii; T Takashima
Journal:  Brain Res       Date:  1996-02-19       Impact factor: 3.252

Review 7.  GABA and behavior: the role of receptor subtypes.

Authors:  R G Paredes; A Agmo
Journal:  Neurosci Biobehav Rev       Date:  1992       Impact factor: 8.989

8.  Upregulation of gamma-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock.

Authors:  K G Lloyd; F Thuret; A Pilc
Journal:  J Pharmacol Exp Ther       Date:  1985-10       Impact factor: 4.030

9.  Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats.

Authors:  A Pilc; A Kłodzińska; P Brański; G Nowak; A Pałucha; B Szewczyk; E Tatarczyńska; E Chojnacka-Wójcik; J M Wierońska
Journal:  Neuropharmacology       Date:  2002-08       Impact factor: 5.250

10.  The GABA(B2) subunit is critical for the trafficking and function of native GABA(B) receptors.

Authors:  Seb J Thuault; Jon T Brown; Steven A Sheardown; Sabine Jourdain; Benjamin Fairfax; Jonathan P Spencer; Sophie Restituito; Josephine H L Nation; Stephanie Topps; Andrew D Medhurst; Andrew D Randall; Andres Couve; Stephen J Moss; Graham L Collingridge; Menelas N Pangalos; Ceri H Davies; Andrew R Calver
Journal:  Biochem Pharmacol       Date:  2004-10-15       Impact factor: 5.858

View more
  18 in total

1.  Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats.

Authors:  Styliani Vlachou; Neil E Paterson; Sebastien Guery; Klemens Kaupmann; Wolfgang Froestl; Deboshri Banerjee; M G Finn; Athina Markou
Journal:  Eur J Pharmacol       Date:  2011-01-22       Impact factor: 4.432

2.  Blunted 5-HT1A receptor-mediated responses and antidepressant-like behavior in mice lacking the GABAB1a but not GABAB1b subunit isoforms.

Authors:  Laura H Jacobson; Daniel Hoyer; Dominique Fehlmann; Bernhard Bettler; Klemens Kaupmann; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2017-01-09       Impact factor: 4.530

3.  Hippocampal GABA levels correlate with retrieval performance in an associative learning paradigm.

Authors:  Benjamin Spurny; Rene Seiger; Philipp Moser; Thomas Vanicek; Murray B Reed; Eva Heckova; Paul Michenthaler; Alim Basaran; Gregor Gryglewski; Manfred Klöbl; Siegfried Trattnig; Siegfried Kasper; Wolfgang Bogner; Rupert Lanzenberger
Journal:  Neuroimage       Date:  2019-10-10       Impact factor: 6.556

Review 4.  The GABAβ receptor as a target for antidepressant drug action.

Authors:  Subroto Ghose; Michelle K Winter; Kenneth E McCarson; Carol A Tamminga; Salvatore J Enna
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

5.  Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression.

Authors:  Beata Karolewicz; Dorota Maciag; Gillian O'Dwyer; Craig A Stockmeier; Anteneh M Feyissa; Grazyna Rajkowska
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-15       Impact factor: 5.176

6.  The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice.

Authors:  J M Wierońska; M Kusek; K Tokarski; J Wabno; W Froestl; A Pilc
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 7.  GABAergic Regulation of Adult Hippocampal Neurogenesis.

Authors:  Mirjam Sibbe; Akos Kulik
Journal:  Mol Neurobiol       Date:  2016-09-06       Impact factor: 5.590

8.  On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039.

Authors:  Agnieszka Pałucha-Poniewiera; Joanna M Wierońska; Piotr Brański; Katarzyna Stachowicz; Shigeyuki Chaki; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2010-08-12       Impact factor: 4.530

9.  GABAB(1) receptor subunit isoforms differentially regulate stress resilience.

Authors:  Olivia F O'Leary; Daniela Felice; Stefano Galimberti; Hélène M Savignac; Javier A Bravo; Tadhg Crowley; Malika El Yacoubi; Jean-Marie Vaugeois; Martin Gassmann; Bernhard Bettler; Timothy G Dinan; John F Cryan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

10.  Gene expression profiling in postmortem prefrontal cortex of major depressive disorder.

Authors:  Hyo Jung Kang; David H Adams; Arthur Simen; Birgitte B Simen; Grazyna Rajkowska; Craig A Stockmeier; James C Overholser; Herbert Y Meltzer; George J Jurjus; Lisa C Konick; Samuel S Newton; Ronald S Duman
Journal:  J Neurosci       Date:  2007-11-28       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.